 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...3233343536373839404142...7475» |
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Pharmacokinetic profile of the port delivery system with ranibizumab (PDS) in the phase 2 ladder trial (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_497;
P2
The serum levels of ranibizumab correlated with aqueous levels. The PDS implant continues to release ranibizumab for an extended period of time, including through month 16 in the PDS 100 mg/mL arm.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment switch from aflibercept to ranibizumab in Canadian DME patients in a real-world setting: the PRECISE study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_488;
Data from enrolled patients thus far showed that the key reason for treatment switch to RBZ-PFS was lack of response to aflibercept treatment, primarily due to presence of fluid in the macula. Preliminary results from completers demonstrated a reduction in CRT, with maintenance of visual acuity and safety.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Visual and anatomical outcomes in patients with or without macular atrophy development when treated with ranibizumab or aflibercept on a treat-and-extend regimen over a 24-Month period: Secondary analysis from the RIVAL study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_487;
Visual acuity improved in patients who developed MA over 12 or 24 months. Patients with no MA at baseline who developed MA before Month 12 and 24 showed better outcomes compared to those with MA at baseline.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Insights from survival analyses during 12 years of anti-VEGF therapy for neovascular age-related macular degeneration (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_485;
Modelling with multiple covariates reveals important factors that help prognosticate individual visual trajectories.Using these models, we demonstrate that an eye beginning anti-VEGF therapy is most likely to experience a positive visual outcome within the first 2 years of initiating treatment and that this is typically sustained for 1.1 years. Furthermore, we underline the need for early detection of neovascular AMD and initiation of anti-VEGF therapy as key factors in improving patient outcomes.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Course of sub-retinal fluid over 10 years in patients with neovascular age related macular degeneration and impact on visual acuity (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_469;
From second year, all categories of SRF recorded decline in VA to year 10 even in the absence of IRF. The slowest decline was noted in the group where SRF persisted at each recorded visit.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] The MATE study: a 24-month, pilot, randomised controlled trial comparing standard care with individualized treat and extend regimen with intravitreal aflibercept for neovascular age - related macular degeneration – MacTSQ and MacDQOL outcomes (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_468;
We present preliminary patient reported outcome measures (PROMs) data from comparing two treatment regimens for aflibercept in the treatment of neovascular AMD. Both arms show a decrease in treatment satisfaction at the end of 2 years,more so in the T&E arm as shown by MacTSQ scores.The impact on quality of life measured by MacDQoL scores show a slight positive change from baseline in SC arm.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Choroidal neovascular membranes: single injection response rate (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_467;
Only 4/61 patients recurred within a 24 month follow up period. These patients responded well to a second injection and only one of these patients required to be switched over to a treat and extend protocol for maintenance of visual gain.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration (nAMD) in Switzerland (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_466;
Nonadherence was associated with loss of vision, lower number of injections that led to extended injection intervals beyond 12 weeks. The results emphasize the importance of adherence to treatment, the need of solutions with greater durability in order to improve and maintain vision, and should be part of counseling patients with nAMD.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Real-world anti-VEGF treatment patterns and outcomes over 3 years in patients with neovascular age-related macular degeneration in the United Kingdom (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_460;
Anti-VEGF switching occurs considerably more frequently in patients initiating BEV or RAN compared to AFL. If the injection interval with current anti-VEGF agents is extended from 8 weeks to 12 weeks, the proportion of eyes maintaining stable dosing during the post-loading phase falls appreciably.
- || zifibancimig (RG6120) / Roche
New P1 trial: BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 27, 2020
P1, N=50, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, P3 data, Journal: Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study. (Pubmed Central) - Sep 27, 2020
P3
Ranibizumab treatment resulted in visual and anatomic gains at 12 months for both retreatment strategies, with a trend in favor of OCT-guided vs BCVA loss guided retreatment. No new safety signals were seen.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. (Pubmed Central) - Sep 27, 2020
Patient delay, diagnosis accuracy, indication for and application of treatment can potentially be improved to improve treatment outcomes. In a value-based care perspective, systematic evaluation of diagnostic accuracy, treatment indication, protocols, and outcomes of new interventions is needed at an early stage to improve outcomes.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. (Pubmed Central) - Sep 27, 2020
In a value-based care perspective, systematic evaluation of diagnostic accuracy, treatment indication, protocols, and outcomes of new interventions is needed at an early stage to improve outcomes. The available RCT evidence suggests that treatment of MO secondary to BRVO with anti-VEGF improves visual and anatomical outcomes at six and 12 months.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal, HEOR, Real-World Evidence: Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. (Pubmed Central) - Sep 26, 2020
RBZ-treated patients reported gains in VA versus baseline; however, the magnitude of the gain in VA was not comparable to the VA gains reported in the RBZ pivotal RCT. Intravitreal treatment with aflibercept was associated with better mean VA outcomes and an incremental gain in QALYs compared with RBZ and can be considered cost-effective for the treatment of nAMD in patients in France despite a higher price for each individual intravitreal injection of aflibercept compared with RBZ.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. (Pubmed Central) - Sep 25, 2020
Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD)...In the present study, vision was retained at baseline level after the four-year treatment with aflibercept. The status of ELM, vitreoretinal adhesion, and choroidal thickness were predictive factors for final vision.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections. (Pubmed Central) - Sep 25, 2020
Administration of topical oxymetazoline 30 minutes before IVI is a single, harmless, cost-effective intervention that decreases the incidence of subconjunctival hemorrhage. This may considerably improve patient treatment satisfaction and promote compliance to IVI therapy.
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical Trial,Phase III, Journal: Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. (Pubmed Central) - Sep 24, 2020
Models with multiple components better predict utility than those with single components. This article provides a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions, resulting in unfounded assumptions about the distribution of the dependent variable.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. (Pubmed Central) - Sep 23, 2020
This article provides a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions, resulting in unfounded assumptions about the distribution of the dependent variable. For eyes with DME, parafoveal VD in the superficial layer at baseline was an independent predictor for visual improvement after the loading ranibizumab treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab. (Pubmed Central) - Sep 23, 2020
For eyes with DME, parafoveal VD in the superficial layer at baseline was an independent predictor for visual improvement after the loading ranibizumab treatment. No abstract available
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Incidence of glaucoma surgeries related to intravitreal Anti-VEGF injections () - Sep 23, 2020 - Abstract #ESCRS2020ESCRS_1737;
To the best of our knowledge, according to the most recent literature review, this inflated number of glaucoma surgeries related to Anti-VEGF treatment has not been reported worldwide. The incidence of surgical glaucoma among this rising population of patients seems to be a local health problem that requires active discussion for further understanding.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Angioid streaks complicated by choroidal neovascularization () - Sep 23, 2020 - Abstract #ESCRS2020ESCRS_1015;
CNV was treated with 3 monthly intravitreal injections of ranibizumab. Angioid streaks are a rare pathology that requires regular monitoring and ophthalmological control in order to quickly diagnose a neovascular complication requiring targeted and early treatment with intravitreal injection of Anti VEGF.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Capsular irrigation with Anti-VEGF in paediatric cataract surgery () - Sep 23, 2020 - Abstract #ESCRS2020ESCRS_460;
However, it showed no additional benefits in preventing visual axis opacification. Further studies on large sample are recommended.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis. (Pubmed Central) - Sep 23, 2020
The treat-and-extend regimen proved to be the most effective regimen for each anti-VEGF drug in the NMA. Pegaptanib every 6 weeks and Conbercept quarterly are unable to satisfy the best corrected visual acuity (BCVA) improvement requirement of nAMD patients.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal, HEOR: Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. (Pubmed Central) - Sep 23, 2020
The potential benefits of conbercept, aflibercept, and ranibizumab has been reported in patients with wet age-related macular degeneration (wAMD)...Probabilistic sensitivity analysis (PSA) indicated that IVT-CON yielded the greatest probabilities of cost-effectiveness (about 92%) compared with other strategies. Conbercept is a cost-effective option for the treatment of wAMD in a Chinese healthcare setting.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. (Pubmed Central) - Sep 21, 2020
Aflibercept-treated eyes, which had borderline worse vision and thicker maculae at baseline, showed larger CST reductions after 12 months of treatment. Larger VA gains were observed with aflibercept treatment when the initial VA was 20/50 or worse.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Survey among retina specialists in Brazil about inflammatory reactions after intravitreal antiangiogenic therapy. (Pubmed Central) - Sep 21, 2020
Aflibercept was the most common agent used. The causes of inflammation remain unknown, but we formulated some relevant hypotheses.
- || Lucentis (ranibizumab) / Roche, Novartis
Novartis, Roche fined $526 million in France for alleged Lucentis marketing 'missteps' https://t.co/dHUtuPNF9G #Healthinnovations #Health #drugscandal #drugs #FDA via @FiercePharma (Twitter) - Sep 17, 2020
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Simultaneous interference of SP1 and HIF1α retarding the proliferation, migration, and invasion of human microvascular endothelial cells (HMEC-1) under hypoxia. (Pubmed Central) - Sep 17, 2020
Simultaneous inhibition of SP1 and HIF1α effectively decreased the activity of HMEC-1 under hypoxic conditions through the CD39-CD73-adenosine and VEGF angiogenesis pathways. Our study may provide a new approach to the treatment of retinal neovascular diseases.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Effects of Huangban Bianxing One decoction combined with ranibizumab on treating exudative age-related macular degeneration. (Pubmed Central) - Sep 16, 2020
HBOD combined with ranibizumab can improve visual acuity and reduce hemorrhage and fluorescein leakage of patients with exudative AMD. These results also indicated that HBOD may function as an effective and safe adjuvant drug for exudative AMD.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Potential roles of MNREAD acuity charts and contrast/glare sensitivity in Ranibizumab treatment of branch retinal vein occlusion. (Pubmed Central) - Sep 16, 2020
MNREAD and CGS testing were useful for evaluating BRVO treatment efficacy. MRS might be a valuable index for evaluating treatment success and making treatment decisions.
- ||||| Lytenava (bevacizumab-vikg) / Outlook Therap
Trial completion: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 15, 2020
P3, N=61, Completed, Sponsor: Outlook Therapeutics, Inc.
MRS might be a valuable index for evaluating treatment success and making treatment decisions. Active, not recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Identifying risk factors for silicone oil droplets in anti-VEGF injections: a quantitative in vitro study () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_301;
Syringes containing anti-VEGF agents release over 100 times more silicone oil droplets compared to syringes with sterile water, suggesting a possible interaction between the anti-VEGF molecules and SiO. The “Heavy force” technique is associated with an increased number of SiO droplets per trial.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure Optimization and Use of Virtual Reality (VR) Simulators in PDS Trials () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_274;
P2, P3
Prophylactic laser ablation of the exposed pars plana before incision and PDS implant insertion was effective in mitigating VH in Ladder, and adherence to the specified surgical methodology was key to success with the optimized procedure. Archway was the first ophthalmic trial to offer surgeons simulated practice of procedures using VR technology to enhance surgical readiness and maximize patient outcomes.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Clinical Trial Versus Real-world Outcomes With AntiVascular Endothelial Growth Factor Therapy for Central Retinal Vein Occlusion () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_256;
P=N/A, P3
In real-world and LTE studies, patients with CRVO had less frequent visits, received fewer anti-VEGF injections, and did not achieve or maintain vision gains observed in clinical trials. These data highlight the need for new strategies that extend the durability of treatment for macular edema in CRVO, reduce treatment burden, and improve real-world vision outcomes.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] The area and number of intraretinal cystoid spaces predict the visual outcome after intravitreal ranibizumab monotherapy in diabetic macular edema () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_214;
The area ratio and number of intraretinal cystoid spaces on initial OCT images were predictors of visual outcome after IVR therapy in DME irrespective of baseline age and BCVA. The factors were related to retinal degeneration in DME and can help obtain proper informed consent before treatment.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Temporal Trends in the Treatment of Proliferative Diabetic Retinopathy: An AAO IRIS Registry Analysis () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_206;
The factors were related to retinal degeneration in DME and can help obtain proper informed consent before treatment. In this cohort analysis of the IRIS Registry, IVI surpassed PRP as the more common method of treating PDR from 2013 to 2017 with bevacizumab administered in more than two-thirds of intravitreal injections.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] What Happens to Diabetic Retinopathy Severity With Less Frequent Treatment? A Post Hoc Analysis of the RISE/RIDE Open-Label Extension Study () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_205;
P3
Regardless of baseline DRSS, patients received an average of 4–5 injections during OLE, suggesting that continuous long-term monitoring and treatment may be necessary to maintain DRSS stability. More severe baseline DR may be indicative of reduced ability to maintain or improve DRSS gains, and greater susceptibility to regress to baseline DRSS with intermittent dosing.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti VEGF Resistant Subretinal Fluid is Associated with Reduced Risk of Macular Atrophy and Better Visual Acuity () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_198;
P3
Additionally, in eyes with no evidence of MA at baseline, rates of MA after 12 or 24 months were significantly higher when SRF was absent. These findings corroborate earlier analyses.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Is Residual Subretinal Fluid (SRF) Associated With Improved Vision Outcomes? Evaluation of Fluorescein Angiography (FA) Patterns From the HARBOR trial () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_190;
P3
In all eyes, presence of SRF was associated with lower rates of MA and fibrosis, but higher rates of PEDs. Further analyses are warranted.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Pharmacokinetic (PK) Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 2 Ladder Trial () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_189;
P2
The PDS implant continuously releases ranibizumab for extended durations, including through M16 in the PDS 100 mg/mL arm. These findings provide PK data to support median time to first refill of 15.8 months observed in PDS 100 mg/mL patients, which was associated with sustained visual gains comparable with monthly intravitreal ranibizumab.
- Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Profiles of Patients Who Initiated Brolucizumab for Neovascular (Wet) Age-related Macular Degeneration in the IRIS Registry () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_183;
The majority of wet AMD patients initiating brolucizumab switched from a prior anti-VEGF agent. Unmet needs continue to exist for many wet AMD patients, as demonstrated by switching to brolucizumab.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-exudative AMD Trial (PREVENT): A prospective controlled clinical trial () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_182;
After 2-year follow-up, conversion to Ex-AMD in high-risk NE-AMD eyes was equal (7 of 54; 13%) in the SHAM and IVR Group. Quarterly intravitreal ranibizumab in high-risk NE-AMD eyes did not prevent conversion to Ex-AMD.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Does Month 3 Response to Ranibizumab Predict Long-term Response to Treatment in Patients With Age-Related Macular Degeneration? () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_174;
P3
A 3-month trial of an anti-VEGF treatment before deciding to switch may not be adequate for the full benefit of treatment to be demonstrated. Further biomarkers are needed to predict long-term nAMD outcomes.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Interrelationships Between Macular Neovascularization Lesion Type, Retinal Fluid Location, and Visual Outcomes in the HARBOR Trial () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_172;
P3
There was a trend towards better BCVA gains among monthly- versus PRN-treated Type 2/M eyes. Overall, Type 1 eyes had the highest mean BCVA over time regardless of concurrent residual SRF.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF Optic Neuropathy (AVON) () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_170;
We present a consecutive series of patients treated with anti-VEGF agents against age matched controls, noting an increased rate of POAG, OHT, and glaucoma suspect in the IVI group. Interestingly, the rates of POAG and OHT were strongly correlated with the number of IVI.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Disease Activity and Anti-VEGF Treatment Patterns in a Commercially Insured US Patient Population with Neovascular Age-Related Macular Degeneration () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_168;
In a real-world setting, active CNV is the most common presenting diagnosis and transition to an inactive/quiescent status is limited. Similar to previous studies, overall rates and frequency of aVEGF treatment in this commercially insured population remains low compared with clinical trials.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Clinical Significance of DR Improvement: A Meta-Analysis of Vision and Anatomic Outcomes in Five Clinical Trials Evaluating IVT Ranibizumab () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_136;
P3
Similar to previous studies, overall rates and frequency of aVEGF treatment in this commercially insured population remains low compared with clinical trials. In a meta-analysis of patients with DR receiving monthly ranibizumab, there was a trend for better vision outcomes and reduction in CST in patients experiencing greater DR severity improvements.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Has the Time Come to Re-evaluate the Treatment Paradigm for Diabetic Retinopathy? () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_135;
Meanwhile, landmark trials showed that patients with moderately severe or severe NPDR were vulnerable to DR progression without treatment, and more likely to achieve DR improvement with anti-VEGF therapy. Given the trend towards greater mean vision gains with greater DR improvement in RIDE/RISE, these data collectively suggest that the time has come to consider earlier intervention to delay progression towards PDR.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System with Ranibizumab (PDS) for Patients With nAMD () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_119;
P3
The phase 3 Archway trial of the PDS XXXX its primary endpoint and demonstrated statistical XXXXXXXXXXX of PDS 100 mg/mL Q24W to monthly intravitreal ranibizumab 0.5 mg. Overall, PDS treatment was XXXX (safety statement).
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Reduced Incidence of Post-Injection Endophthalmitis with Pre-filled Syringes () - Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_68;
However, a lower incidence of endophthalmitis was found for prefilled syringes and in offices where physicians, as opposed to nurses or technicians, drew up the medication. The use of prefilled syringes and increased caution while drawing up of drug from vials may lower the incidence of endophthalmitis.